Breaking News Instant updates and real-time market news.


Cellectar Biosciences


0.02 (0.74%)


Cellectar Biosciences issued formal patent allowance from USPTO for CLR 1603

Cellectar Biosciences announces that the United States Patent and Trademark Office, or USPTO, has issued a formal patent allowance for CLR 1603, which covers method of use for the treatment of a variety of solid tumors and associated cancer stem cells using the company's phospholipid drug conjugate, or PDC, delivery platform technology with paclitaxel. This patent allowance follows the May 2016 issuance of the composition of matter patent for the same compound. CLR 1603 is a form of paclitaxel conjugated to the company's patented phospholipid drug conjugate delivery platform using a simple compound linker. The USPTO patent allowance covers method of use for breast, pancreatic, lung, colorectal and prostate cancers. The company expects the full patent to be granted by the end of 2016.


Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.